Xiamen Humanity Hospital
Leiomyosarkoma treatment cost in China typically runs from $19,500 to $47,500 for surgical removal, while specialized interventions like CyberKnife sessions range from $9,200 to $18,000. Total expenses depend on the cancer stage, hospital tier, and the need for complex multidisciplinary care. Patients often see 40-60% savings compared to the US. Top cities for this treatment include Guangzhou, Beijing, and Shanghai.
Typical Leiomyosarcoma Treatment Costs in China
Bookimed Expert Insight: Advanced-stage patients benefit most from centers offering alternatives to traditional systemic therapy. Fuda Cancer Hospital specializes in minimally invasive options like NanoKnife and cryosurgery for complex cases. These technologies are ideal for patients who cannot tolerate aggressive chemotherapy. JCI-accredited facilities in Guangzhou provide multidisciplinary care for over 30,000 international patients. Tertiary hospitals like Xiamen Humanity Hospital offer high-volume surgical expertise with 1,000 inpatient beds.
| China | Turkey | Austria | |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Radiation Therapy for Sarcomas | from $10,500 | from $3,250 | from $18,000 |
| Proton-beam therapy | from $36,500 | from $70,000 | from $80,000 |
| Proton therapy for prostate cancer | from $42,500 | from $30,000 | from $80,000 |
| Proton therapy for breast cancer | from $38,500 | from $30,000 | from $55,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
First-line treatment for Leiomyosarcoma in China prioritizes complete surgical resection with negative margins for localized tumors. Advanced cases utilize anthracycline-based chemotherapy. Chinese protocols uniquely integrate domestic multi-kinase inhibitors like anlotinib alongside standard systemic therapies. Tertiary hospitals often provide precision technologies like CyberKnife or proton therapy.
Bookimed Expert Insight: China's oncology landscape offers a unique high-volume advantage for complex cases. Xiamen Humanity Hospital alone serves 1,000,000 patients annually. Large tertiary centers like Fuda Cancer Hospital utilize specialized interventions like cryosurgery and NanoKnife. This high throughput ensures surgeons maintain proficiency in rare soft tissue malignancies.
Patient Consensus: Patients emphasize finding a specialized sarcoma surgeon initially to avoid poor first operations. They note that pathology results often change after expert review at major tertiary hospitals.
China manages uterine leiomyosarcoma (uLMS) through aggressive surgical protocols and advanced precision medicine research. Treatment centers focus on secondary cytoreductive surgery for recurrences. They also integrate AI-driven pathology to counteract high rates of initial surgical misdiagnosis. Most facilities utilize multi-omics subtyping to predict chemotherapy responses.
Bookimed Expert Insight: China's oncology infrastructure is uniquely divided between high-volume tertiary centers and smaller local hospitals. Data shows Xiamen Humanity Hospital serves approximately 1,000,000 patients annually. Large-scale institutions like this are essential for rare diseases like uLMS. They provide the necessary volume to support clinical trials and advanced technologies like CyberKnife M6. Smaller hospitals may not offer the same diagnostic precision for sarcoma.
Patient Consensus: Patients note it is important to avoid tissue fragmentation during surgery if sarcoma is suspected. They emphasize seeking expert pathology reviews at major academic centers to ensure the correct treatment plan.
Leading Chinese oncology centers for Leiomyosarcoma include Fuda Cancer Hospital and Xiamen Humanity Hospital. These facilities specialize in multidisciplinary care for rare soft-tissue sarcomas. They integrate JCI-accredited safety standards with advanced minimally invasive technologies like NanoKnife and precision radiation to optimize patient outcomes.
Bookimed Expert Insight: Patient volume serves as a critical quality indicator in China. Xiamen Humanity Hospital treats approximately 1,000,000 patients annually. This high throughput ensures medical teams maintain expertise in rare pathologies like Leiomyosarcoma. Smaller clinics may lack the required multidisciplinary depth for complex resections.
Patient Consensus: Patients emphasize that securing a sarcoma-specific pathologist for the initial review is vital. They recommend choosing high-volume centers in major hubs to ensure surgeons have routine experience with rare soft-tissue tumors.
Chinese oncology centers provide advanced leiomyosarcoma treatments like vascular interventional therapy, CyberKnife M6 radiosurgery, and cryosurgery when chemotherapy fails. Facilities focus on precision destruction of tumors using NanoKnife or microwave hyperthermia. Specialized protocols often include anti-angiogenic TKIs like Apatinib to restrict tumor blood supply.
Bookimed Expert Insight: Xiamen Humanity Hospital stands out for its massive scale, treating 1,000,000 patients annually with 47 clinical departments. This high volume often translates to faster access for clinical drug trials. Patients should prioritize clinics like this when seeking Phase I–IV academic trials for refractory sarcomas. Professor Liu Shi Xin at Xiamen is a national expert in precision radiotherapy, which is vital for late-stage local control.
Patient Consensus: Patients emphasize that full molecular profiling is essential before starting new treatments to find actionable targets. Many note that high-volume university hospitals are often more willing to coordinate combined radiation and systemic therapy rapidly.
China hosts active immunotherapy trials and combination therapies for leiomyosarcoma (LMS). Research focuses on pairing PD-1 inhibitors with anti-angiogenic agents, targeted therapies, or epigenetic regulators. These approaches help penetrate cold tumors. Major oncology centers in Guangzhou and Xiamen facilitate these advanced protocols.
Bookimed Expert Insight: Patient volume deeply impacts trial access in China. Xiamen Humanity Hospital serves approximately 1,000,000 patients annually. This massive scale often correlates with accreditation for Phase I-IV drug trials. Large-scale tertiary hospitals are more likely to offer these experimental combination protocols than smaller oncology clinics.
Patient Consensus: Patients note that immunotherapy is rarely used alone for LMS. Most discussions focus on finding specific trials that combine checkpoint inhibitors with targeted treatments or regional protocols.
Traditional Chinese Medicine serves as a supportive care layer alongside conventional surgery, radiation, and chemotherapy. Integrated protocols focus on managing treatment side effects like nausea and fatigue. It optimizes constitutional health and systemic recovery without replacing definitive oncological interventions for sarcoma.
Bookimed Expert Insight: Patients should note that leading Chinese centers like Xiamen Humanity Hospital and Fuda Cancer Hospital emphasize clinical trials and advanced technologies like NanoKnife alongside traditional roots. The most effective strategy involves securing a precise diagnosis and surgical plan at these high-volume tertiary hospitals before layering in TCM for recovery. This ensures aggressive sarcoma care remains the primary focus while utilizing traditional methods for long-term well-being.
Patient Consensus: Patients emphasize that TCM should be used to feel better during recovery rather than to shrink tumors. They strongly advise informing the oncology team about all herbal supplements to avoid interactions with anesthesia or chemotherapy.